Capillary blood collection and sampling devices play a crucial role in diabetes management by enabling individuals to conveniently monitor their blood glucose levels at home. These devices utilize lancets to obtain small blood samples from the fingertip, which are then analyzed using a glucometer. This point-of-care testing allows for timely adjustments in diet, exercise, and medication to maintain optimal blood sugar control. Additionally, capillary blood collection devices find applications beyond diabetes, such as in point-of-care testing for various other health conditions where minimal blood volume is required for diagnostic purposes.
Global Capillary Blood Collection and Sampling Devices Market valued at USD 2,539.66 million in 2022, is projected to reach 3625.50 million by 2030 and will grow at a CAGR of 4.55% during the forecast period of 2023-2030.
To know more, visit https://www.databridgemarketresearch.com/reports/global-capillary-blood-collection-and-sampling-devices-market
Below are the Top Capillary Blood Collection and Sampling Devices companies with a Significant Market Share:
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
1.
|
Cardinal Health
|
Cardinal Health offers a range of capillary blood collection and sampling devices designed to meet the needs of healthcare professionals worldwide. Their products are known for their quality and reliability, contributing to their significant presence in the global market.
|
|
U.S.
|
In May 2007, Cardinal Health signed an acquisition agreement with VIASYS, a company which is engaged in manufacturing of diagnostics solutions. As the capillary blood collection devices are used for diagnosis of various kinds of disease, this acquisition helped the company to enhance its platform for capillary blood collection devices, moreover helped the company to earn immediate revenues.
|
2.
|
BD
|
BD is a leading provider of medical devices and solutions, including capillary blood collection and sampling devices. With a focus on innovation and customer satisfaction, BD's products are widely utilized in healthcare settings globally, driving their strong position in the market.
|
|
Europe, U.S., and Asia-Pacific
|
In March 2020, BD along with BioMedomics, a privately held, North Carolina-based clinical diagnostics company announced that they have developed a rapid test to check the current exposure of COVID 19 within 15 minutes at home. This is a novel testing device and will lead to increased revenue generation.
|
3.
|
F. Hoffmann-La Roche Ltd.
|
Roche offers a comprehensive portfolio of capillary blood collection and sampling devices. Renowned for their advanced technology and commitment to improving patient care, Roche's products are trusted by healthcare professionals worldwide.
|
|
Europe, Africa, America, Oceania, and Asia
|
In August 2016, F. Hoffmann-La Roche Ltd launched Accu-Chek Guide, the next-generation blood glucose monitoring system. This device has utilized the capillary blood collected by using ACCU-CHEK Safe-T-Pro Plus Lancet. This launch helped the company to broaden its product portfolio of capillary blood collection devices.
|
4.
|
B. Braun SE
|
B. Braun is a respected name in the healthcare industry, known for its high-quality medical devices and solutions. Their capillary blood collection and sampling devices are designed to provide accurate and efficient sample collection, contributing to their significant presence in the global market.
|
|
Europe, Middle East and Africa, South America, North America, and Asia-Pacific
|
In April 2018, B. Braun Melsungen AG opened 5 new medical production facilities in Malaysia. This has increased the manufacturing of medical devices and pharmaceutical. This helped in increasing the production as well as the revenue of the organisation.
|
5.
|
Abbott
|
Abbott is known for its diverse portfolio of medical devices and diagnostics solutions. Their capillary blood collection and sampling devices are widely used in clinical settings, reflecting Abbott's commitment to innovation and improving healthcare outcomes globally.
|
|
Europe, Americas, Middle East and Africa, Greater China, and Asia-Pacific
|
In June 2019, Abbott launched AfinionHbA1c Dx assay to be use with Afinion 2 Analyzer in order to provide rapid point of care test for patients suffering from diabetes. This device uses capillary blood sample in order to deliver accurate glycated haemoglobin results in only three minutes. This product launch helped the company to enhance its platform of capillary blood collective device and to generate more revenue by product sales.
|
Conclusion
In the global capillary blood collection and sampling devices market, Cardinal Health, BD, F. Hoffmann-La Roche Ltd., B. Braun SE, and Abbott stand out as key players, each contributing significantly with their diverse product offerings and commitment to quality and innovation. Their presence underscores the importance of reliable and efficient capillary blood collection and sampling devices in healthcare settings worldwide. As the market continues to evolve, these companies are poised to play pivotal roles in shaping its trajectory, driving advancements in technology and improving patient care outcomes on a global scale.